Loading...
XNAS
MRSN
Market cap138mUSD
Dec 05, Last price  
27.78USD
1D
1.11%
1Q
307.26%
IPO
105.44%
Name

Mersana Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:MRSN chart
P/E
—
P/S
3.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-35.38%
Rev. gr., 5y
-0.78%
Revenues
40m
+9.88%
10,359,00025,171,00017,545,00010,594,00042,123,000828,00043,00026,581,00036,855,00040,497,000
Net income
-69m
L-59.69%
-16,428,000-13,700,000-38,707,000-64,257,000-27,197,000-88,404,000-169,205,000-207,540,000-171,670,000-69,192,000
CFO
-82m
L-51.24%
-9,636,00031,588,000-42,679,000-55,216,000-67,744,000-74,696,000-139,988,000-49,363,000-168,882,000-82,340,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
URL
https://www.mersana.com/
IPO date
Jun 28, 2017
Employees
228
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT